ONO Pharmaceutical Co (4528) AI Stock Analysis

• Market Cap: $721.61B
• Dividend Yield: 5.11%
• Average Volume (3M): 2.56M
• Price to Earnings (P/E): 14.4
• Beta (1Y): 0.41
• Revenue Growth: -2.16%
• EPS Growth: -40.39%
• Country: JP
• Employees: 3,853
• Sector: Healthcare
• Sector Strength: 43
• Industry: Drug Manufacturers - General
• EPS (TTM): -13.94
• Shares Outstanding: 498,692,800
• 10 Day Avg. Volume: 3,240,220
• 30 Day Avg. Volume: 2,563,580
• PEG Ratio: -0.45
• Price to Book (P/B): 0.90
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 9.37
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $1,399.60
• Price Target Upside: -8.91% Downside
• Rating Consensus: Moderate Sell
• Number of Analyst Covering: 1

• Rating: 75 Outperform
• Price Target: ―

ONO Pharmaceutical Co is supported by strong financial performance, underscored by robust profitability and financial management. The valuation is attractive with a reasonable P/E ratio and a good dividend yield. Technical analysis indicates a neutral trend, with potential upward momentum suggested by the MACD. The lack of recent earnings call data limits insight into future guidance.

ONO Pharmaceutical Co Business Overview & Revenue Model

Company Description

ONO Pharmaceutical Co., Ltd. is a Japanese pharmaceutical company headquartered in Osaka, Japan. The company specializes in the research, development, manufacturing, and marketing of pharmaceutical products, focusing on areas such as oncology, immunology, and cardiovascular diseases. ONO Pharmaceutical is known for its strong emphasis on innovation, particularly in creating novel therapies that address unmet medical needs.

How the Company Makes Money

ONO Pharmaceutical Co. generates revenue primarily through the sale of its pharmaceutical products. The company's revenue streams are largely driven by the commercialization of its proprietary drugs, which include treatments in areas like oncology and immunology. A significant portion of its income comes from the sales of Opdivo, an immune checkpoint inhibitor used in cancer treatment. Additionally, ONO Pharmaceutical benefits from strategic partnerships and collaborations with other pharmaceutical companies, which help in co-developing and marketing new drugs. These partnerships often involve licensing agreements and milestones that contribute to its financial performance. The company also invests in research and development to sustain its pipeline of innovative drugs, thereby ensuring future revenue growth.

ONO Pharmaceutical Co Financial Statement Overview

Summary

ONO Pharmaceutical Co showcases strong financial health with robust profitability, effective financial management, and consistent revenue growth. The company's low leverage and strong equity base further reinforce its stability and growth potential.

Income Statement

ONO Pharmaceutical Co has demonstrated strong financial performance with a solid Gross Profit Margin of 72.43% and a commendable Net Profit Margin of 15.19% over the TTM (Trailing-Twelve-Months). The company has shown a consistent revenue growth trajectory, with a notable revenue increase of 8.97% from 2023 to 2024. The EBIT Margin of 18.26% and EBITDA Margin of 22.43% further highlight the company's operational efficiency and robust profitability.

Balance Sheet

The balance sheet of ONO Pharmaceutical Co reflects strong financial health with a low Debt-to-Equity Ratio of 0.19, indicating prudent financial leverage. The Return on Equity (ROE) of 9.07% demonstrates effective use of shareholder equity. Additionally, the Equity Ratio stands at 75.40%, showcasing a solid equity base and financial stability.

Cash Flow

ONO Pharmaceutical Co's cash flow analysis reveals a stable financial standing, with a Free Cash Flow to Net Income Ratio of 1.06 and an Operating Cash Flow to Net Income Ratio of 1.25 in the TTM (Trailing-Twelve-Months). While Free Cash Flow experienced a decline of 13.09% compared to the previous year, the company maintains positive cash generation capabilities.

Breakdown
TTM	Mar 2024	Mar 2023	Mar 2022	Mar 2021	Mar 2020
Income Statement		Total Revenue
487.33B	502.67B	447.19B	361.36B	309.28B	292.42B
	Gross Profit
352.95B	375.55B	337.13B	267.85B	223.71B	213.36B
	EBIT
88.99B	163.10B	141.96B	103.19B	98.33B	77.49B
	EBITDA
109.30B	181.98B	167.50B	128.54B	114.54B	94.00B
	Net Income Common Stockholders
74.03B	127.98B	112.72B	80.52B	75.42B	59.70B
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
170.84B	166.14B	164.29B	116.97B	104.97B	100.42B
	Total Assets
1.08T	913.67B	882.44B	739.20B	746.84B	673.44B
	Total Debt
154.29B	8.86B	9.17B	8.80B	9.05B	8.36B
	Net Debt
-6.70B	-157.28B	-86.97B	-60.31B	-51.99B	-60.64B
	Total Liabilities
260.81B	115.06B	134.62B	77.53B	105.69B	105.42B
	Stockholders Equity
815.92B	792.96B	741.87B	655.91B	635.55B	562.48B
Cash Flow		Free Cash Flow
78.08B	89.83B	145.11B	49.55B	53.68B	51.71B
	Operating Cash Flow
92.63B	110.66B	159.61B	61.83B	73.98B	74.16B
	Investing Cash Flow
-123.41B	48.08B	-100.26B	6.04B	-57.59B	-10.23B
	Financing Cash Flow
89.11B	-89.85B	-32.48B	-60.24B	-24.75B	-54.72B

ONO Pharmaceutical Co Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1536.50
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4528, the sentiment is Negative. The current price of 1536.5 is below the 20-day moving average (MA) of 1580.97, below the 50-day MA of 1622.49, and below the 200-day MA of 1743.36, indicating a bearish trend. The MACD of -36.03 indicates Positive momentum. The RSI at 43.02 is Neutral, neither overbought nor oversold. The STOCH value of 51.09 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:4528.

ONO Pharmaceutical Co Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
4507	87 Outperform	¥2.07T	11.75	12.99%	2.67%	1.58%	12.48%
4519	79 Outperform	$12.36T	30.15	22.80%	1.25%	17.96%	25.65%
4503	79 Outperform	$2.46T	48.14	3.22%	5.25%	19.25%	294.48%
4528	75 Outperform	$721.61B	14.42	6.25%	5.11%	-2.16%	-40.39%
4502	68 Neutral	¥6.57T	60.68	1.50%	4.94%	9.83%	15.49%
4523	65 Neutral	¥1.12T	24.27	5.34%	3.93%	5.63%	30.61%
Sector *	53 Neutral	$5.14B	3.06	-43.57%	2.81%	16.81%	-0.12%

ONO Pharmaceutical Co Corporate Events

Ono Pharmaceutical Enhances Governance and Diversity Initiatives

Ono Pharmaceutical Co., Ltd. has announced its commitment to strengthening corporate governance by enhancing the functions of its Board of Directors and Audit & Supervisory Board. The company is also systematically reducing its cross-shareholdings to increase corporate value and is promoting diversity, equity, and inclusion within its workforce to improve employee engagement and unity. These initiatives are expected to positively impact the company’s operations and industry positioning.